Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Joseph P Lyssikatos, Chief Scientific Officer of Enliven Therapeutics NASDAQ:ELVN, sold 1,500 shares of common stock on September 23, 2025, at a price of $20.03, for a total value of $30,045. The transaction occurred as shares traded 38% below analyst high targets of $52, though InvestingPro analysis indicates the stock is currently overvalued.
Following the transaction, Lyssikatos indirectly owns 931,688 shares through The Lyssikatos Revocable Trust.
The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
In other recent news, Enliven Therapeutics has been the focus of attention from analysts following promising developments in its cancer treatment, ELVN-001. BTIG has reiterated its Buy rating for the company, maintaining a price target of $45.00. This decision is based on the potential of ELVN-001, a next-generation tyrosine kinase inhibitor, which is showing promising efficacy and safety in treating chronic myeloid leukemia. Meanwhile, H.C. Wainwright has raised its price target for Enliven Therapeutics from $40.00 to $48.00, while also maintaining a Buy rating. This upgrade comes after updated results from the Phase 1a/1b ENABLE trial, which were presented at the EHA 2025 conference, highlighting the treatment’s progress in heavily pretreated chronic myelogenous leukemia patients. These recent developments reflect the growing confidence in Enliven Therapeutics’ capabilities within the $9 billion market for chronic myeloid leukemia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.